Comparative Pharmacology
Head-to-head clinical analysis: SODIUM ZIRCONIUM CYCLOSILICATE versus VELTASSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM ZIRCONIUM CYCLOSILICATE versus VELTASSA.
SODIUM ZIRCONIUM CYCLOSILICATE vs VELTASSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium zirconium cyclosilicate is a non-absorbed, inorganic, potassium-selective cation exchanger that binds potassium ions in the gastrointestinal tract, thereby reducing the absorption of potassium and facilitating its fecal excretion. It exchanges sodium and hydrogen for potassium in the gut lumen.
VELTASSA (patiromer) is a non-absorbed polymer that binds potassium ions in the gastrointestinal tract, reducing serum potassium levels by increasing fecal potassium excretion.
5 g orally three times daily.
8.4 g (1 packet) orally once daily; titrate to a maximum of 25.2 g (3 packets) once daily as needed to achieve normokalemia.
None Documented
None Documented
Not applicable as the drug acts locally in the GI tract without systemic absorption; clinical effect persists for duration of dosing.
Not applicable due to non-systemic action; patiromer acts locally in the gastrointestinal tract and is not absorbed. Elimination half-life of the polymer is not measurable clinically.
Primarily eliminated unchanged in feces (>99%); negligible renal excretion (<1%) as the drug is not absorbed systemically.
Primarily eliminated via feces as insoluble, non-absorbed polymer (80-90%); minimal renal excretion (<0.01% of administered dose as intact drug in urine), biliary excretion negligible.
Category C
Category C
Potassium Binder
Potassium Binder